Background: Allergen immunotherapy has demonstrated usefulness in the management of allergic diseases such as asthma, allergic rhinitis and conjunctivitis. However, little is known about its effectiveness in vernal keratoconjunctivitis (VKC), a disease mediated by IgE and lymphocytes, that can cause loss of visual acuity in a permanent way.
Objective: To describe safety and effectiveness of allergen immunotherapy in a group of patients with VKC.
Methods: From a sample of 575 patients sensitized to house dust mites, who received ultra-rush immunotherapy for asthma, allergic rhinoconjuctivitis or atopic dermatitis, 28 patients with VKC were selected and a retrospective analysis was performed with the evaluation of factors related to safety, pharmacological treatment and clinical response to immunotherapy..
Results: Twenty eight patients with VKC who received allergen immunotherapy were studied. There were 21 men and 7 women, with an average age of 11 years. A total of 490 doses were administered (35 for build-up and 455 for maintenance) for different periods. The average number of doses per patient was 17. There were no local or systemic reactions. Seventy one percent of the patients presented a clear reduction in the use of medications, with an improvement in symptoms 89% and physical findings 68%.
Conclusions: Allergen immunotherapy seems to be a safe and efficient treatment for patients with VKC, and can contribute along with pharmacological management to the improvement of symptoms and reduction in the use of medications.